Innovation1 Biotech's receivables is $0.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Innovation1 Biotech posts a receivables of $0 as of February 2024. That compares with $56K in the prior-year period — down 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Innovation1 Biotech's receivables was $56K. The latest reading is $0 — a 100.0% year-over-year decrease (period ending February 2024). Use the history and growth charts on this page for a longer lookback.
Receivables is one piece of Innovation1 Biotech's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for IVBT's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Innovation1 Biotech's other metric pages and overview cover the third.